This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1243 entries already.
The European Commission has promised to create a new public-private fund to bridge the ‘valley of death’ phase for technology companies facing expansion. In addition, the EU wants to reduce its lag in the number of technology unicorns compared to the United States and China with a start-up and scale-up strategy.
Foodtech startup Norwegian Mycelium A/S has raised €1.25m in a financing round led by Nippon Beet Sugar Manufacturing Co., Ltd. (Nitten), Japan’s largest beet sugar producer, to scale-up its mycoprotein platform.
For nearly two decades, Roche AG has been searching for a next-generation sequencing method in personalised medicine to overcome the limitations of short read lengths in existing sequencing technologies. Following beta testing, the company plans to launch its new Sequencing by Expansion (SBX) technology commercially next year.
C4X Discovery Holdings Ltd has received a €8m milestone payment from the French pharmaceutical company Sanofi for its preclinical IL-17A inhibitor. This payment is based on a licence agreement from 2021, under which the British company could receive up to €414m, including royalties.
Pharmacologists at the University of Göttingen, Germany, have reported a simple way to target and silence individual mitochondrial mRNAs in vivo.
British company Wildcat Laboratory Solutions Ltd and Hamburg-based mo:re GmbH have received the New Product Award from the Society for Laboratory Automation and Screening (SLAS) in recognition of new technologies with potential to drive industry transformation. The award for the most promising start-up was conferred upon Swiss firm Oryl Photonics SA.
Organised by the Society for Laboratory Automation and Screening (SLAS), SLAS Europe currently is taking place in Hamburg from 20–22 May. As part of a special series, European Biotechnology Magazine is profiling twelve of the most innovative exhibiting SMEs supported under the SLAS AveNew programme. Among them is US-based ThirdLaw Molecular Inc.
BioNTech is set to open a research centre for cancer therapy in the United Kingdom, much to the delight of the British government, which is helping pave the way with a substantial financial boost.
Organized by the Society for Laboratory Automation and Screening (SLAS), the premier automation conference in Europe, the SLAS Europe 2025 (20-22. May 2025), will showcase the latest technologies and drug discovery enablers. As part of its preview series, European Biotechnology Magazine profiles 12 of Europe’s most innovative AveNew SMEs – this edition features Austrian LifeTaq-Analytics GmbH.
British investment firm SV Health Investors has secured US$269m for its second fund, Dementia Discovery Fund, or DDF-2. The capital will be used to invest in companies developing or enabling novel therapeutics for dementia.